Pancreatic Cancer Research

ResearcherUniversity College DublinActive in the last 2 years

David J. Hughes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1668-8770; OpenAlex author ID A5039013705, A5134049873. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Non-coding RNAs as biomarkers and therapeutic targets in pancreatic cancer: Clinical implications and translational perspectives. Co-author DOI 10.1016/j.biopha.2026.119394↗
  2. The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer. Last author DOI 10.1016/j.semcancer.2025.03.002↗
  3. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Co-author DOI 10.1016/j.semcancer.2025.05.004↗
  4. Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study. Co-author DOI 10.1038/s41598-024-77431-5↗
  5. Publisher Correction: Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomi… Co-author DOI 10.1038/s41598-024-83618-7↗
  6. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  7. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
  8. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniele Campa · 6 shared papers, 2017–2026 · strength 1.13
  2. Neil Daniel · 5 shared papers, 2024–2026 · strength 1.09
  3. Cosmeri Rizzato · 5 shared papers, 2017–2025 · strength 0.90
  4. Riccardo Farinella · 4 shared papers, 2024–2025 · strength 0.86
  5. Federico Canzian · 3 shared papers, 2017–2024 · strength 0.43
  6. Pinar Uysal Onganer · 2 shared papers, 2025–2026 · strength 0.43
  7. Juan Sáinz · 2 shared papers, 2025–2026 · strength 0.43
  8. Pavel Souček · 4 shared papers, 2017–2025 · strength 0.42
  9. Ľudmila Vodičková · 2 shared papers, 2017–2025 · strength 0.24
  10. Pavel Vodička · 2 shared papers, 2017–2025 · strength 0.24
  11. Stefano Landi · 2 shared papers, 2017–2025 · strength 0.24
  12. María Carretero-Fernández · 1 shared paper, 2026 · strength 0.23
  13. Annalisa Comandatore · 1 shared paper, 2025 · strength 0.20
  14. Ruggero Ponz de Leon Pisani · 1 shared paper, 2025 · strength 0.20
  15. Lívia Archibugi · 1 shared paper, 2025 · strength 0.20
  16. Giulia Peduzzi · 1 shared paper, 2025 · strength 0.20
  17. Radmila Lemstrová · 3 shared papers, 2017 · strength 0.15
  18. Martin Oliverius · 3 shared papers, 2017 · strength 0.15
  19. Zdeněk Kala · 3 shared papers, 2017 · strength 0.15
  20. Beatrice Mohelníková-Duchoňová · 3 shared papers, 2017 · strength 0.15
  21. Jan Hlavsa · 2 shared papers, 2017 · strength 0.11
  22. R Havlík · 1 shared paper, 2017 · strength 0.05
  23. Martin Loveček · 1 shared paper, 2017 · strength 0.05
  24. Bohuslav Melichar · 1 shared paper, 2017 · strength 0.05
  25. Viktor Hlaváč · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.